N-2-(4-(2-tetrahydrofuryl)methoxyphenyl)propyl 2-propanesulfonamide | 211314-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-2-(4-(2-tetrahydrofuryl)methoxyphenyl)propyl 2-propanesulfonamide
• 英文别名: N-[2-[4-(oxolan-2-ylmethoxy)phenyl]propyl]propane-2-sulfonamide
• CAS: 211314-11-3
• 化学式: C₁₇H₂₇NO₄S
• 分子量: 341.472
• InChiKey: OGIPGDGGKTYKLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  73
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• (BIS)sulfonamide derivatives
  申请人：——

  公开号：US20040054009A1

  公开（公告）日：2004-03-18

  The present invention provides (bis) sulfonamide derivatives of formula (I) useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

  本发明提供了公式(I)的(双)磺胺衍生物，可用于增强哺乳动物的谷氨酸受体功能，因此可用于治疗多种疾病，如精神疾病和神经系统疾病。
• [EN] N-SUBSTITUTED SULFONAMIDE DERIVATIVES<br/>[FR] SULFAMIDES N-SUBSTITUES
  申请人：LILLY CO ELI

  公开号：WO2000006537A1

  公开（公告）日：2000-02-10

  The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

  本发明提供了一些N-取代磺酰胺衍生物，用于增强哺乳动物的谷氨酸受体功能，因此，用于治疗广泛的疾病，如精神和神经系统疾病。
• Sulphonamide derivatives
  申请人：——

  公开号：US20020002158A1

  公开（公告）日：2002-01-03

  Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R 1 —L—NHSO 2 R 2 I in which R 1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R 2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R 3 R 4 N in which R 3 and R 4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are novel compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.

  一种具有公式R1-L-NHSO2R2的化合物的有效量可以增强哺乳动物中的谷氨酸受体功能，其中R1表示未取代或取代的芳香或杂环芳香基团；R2表示（1-6C）烷基，（3-6C）环烷基，（1-6C）氟烷基，（1-6C）氯烷基，（2-6C）烯基，（1-4C）烷氧基（1-4C）烷基，苯基，该苯基未取代或通过卤素，（1-4C）烷基或（1-4C）烷氧基取代，或公式R3R4N的基团，其中R3和R4各自独立地表示（1-4C）烷基，或者与它们所连接的氮原子一起形成一个氮杂环基团，包括氮杂丙环基团，吡咯环基团，哌啶环基团，吗啉环基团，哌嗪环基团，六氢氮杂环基团或八氢氮杂环基团；L表示未取代或通过（1-6C）烷基，芳基（1-6C）烷基，（2-6C）烯基，芳基（2-6C）烯基和芳基中选择的一种或两种独立选择的取代基取代的（2-4C）烷基链，或者通过两种取代基与它们所连接的碳原子或碳原子一起形成一个（3-8C）碳环；以及其药学上可接受的盐。还公开了公式I的新化合物，制备它们的过程以及包含它们的制药组合物。
• SULPHONAMIDE DERIVATIVES
  申请人：Arnold B. Macklin

  公开号：US20060030599A1

  公开（公告）日：2006-02-09

  Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R 1 -L-NHSO 2 R 2 I in which R 1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R 2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C) chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R 3 R 4 N in which R 3 and R 4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are novel compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.

  一种化合物可以增强哺乳动物中谷氨酸受体的功能，该化合物的化学式为R1-L-NHSO2R2，其中R1表示未取代或取代的芳香或杂芳基团；R2表示(1-6C)烷基，(3-6C)环烷基，(1-6C)氟代烷基，(1-6C)氯代烷基，(2-6C)烯基，(1-4C)烷氧基(1-4C)烷基，苯基，未取代或取代的卤素、(1-4C)烷基或(1-4C)烷氧基，或者公式R3R4N的基团，其中R3和R4各自独立地表示(1-4C)烷基，或者与它们连接的氮原子一起形成氮杂环丙烷基、吡咯烷基、哌啶基、吗啉基、哌嗪基、六氢氮杂环庚烷基或八氢氮杂环二十烷基；L表示未取代或取代的(2-4C)烷基链，该链通过一个或两个独立选择的取代基未取代或取代，这些取代基是(1-6C)烷基，芳基(1-6C)烷基，(2-6C)烯基芳基(2-6C)烯基芳基，或者通过两个取代基与它们连接的碳原子或碳原子形成(3-8C)环状碳基环；以及其药学上可接受的盐。还公开了公式I的新化合物，制备它们的方法以及含有它们的制药组合物。
• Sulphonamide Derivatives
  申请人：Eli Lilly & Company

  公开号：EP1528055A2

  公开（公告）日：2005-05-04

  The present invention provides compounds of the formula: wherein R14 represents a phenyl group which is unsubstituted or substituted by one or two of halogen; nitro; cyano; (1-10C) alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl; halo(1-10C)alkyl; (CH2)zX3R15 in which z is 0 or an integer of from 1 to 4, X3 represents O, S, NR16, CO, COO, OCO, CONR17, NR18CO, OCONR19, R15 represents hydrogen, (1-10C) alkyl, (3-10C)alkenyl, (3-10C)alkynyl or (3-8C)-cycloalkyl and R16, R17, R18 and R19 each independently represents hydrogen or (1-10C)alkyl, or R15 and R16, R17, R18 or R19 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group; or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising these compounds.

  本发明提供了式中化合物： 其中 R14 代表未被取代或被卤素、硝基、氰基、(1-10C)烷基、(2-10C)烯基、(2-10C)炔基、(3-8C)环烷基、卤代(1-10C)烷基中的一个或两个取代的苯基；(CH2)zX3R15 其中 z 是 0 或 1 至 4 的整数，X3 代表 O、S、NR16、CO、COO、OCO、CONR17、NR18CO、OCONR19，R15 代表氢、(1-10C)烷基、(3-10C)烯基、(3-10C)炔基或(3-8C)环烷基，R16、R17、R18和R19各自独立地代表氢或(1-10C)烷基，或R15和R16、R17、R18或R19与它们所连接的氮原子一起形成氮杂环丁基、吡咯烷基、哌啶基或吗啉基；或其药学上可接受的盐。还公开了包含这些化合物的药物组合物。